BLTE
NASDAQ
US
Belite Bio, Inc - American Depositary Shares
$169.85
▲ +$2.60
(+1.55%)
Vol 214K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.6B
ROE
-32.5%
D/E
0.00
Beta
-1.43
52W
$49–$162
Wall Street Consensus
14 analysts · Apr 20264
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
VTRS
Viatris Inc
$14.3B
AXSM
Axsome Therapeutics Inc
$9.2B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
Earnings
Beat rate: 0.0%
Next Report
May 11, 2026
EPS Estimate: $-0.65
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.65 | — | — |
| Dec 2025 | $-0.56 | $-0.70 | $-0.14 |
| Sep 2025 | $-0.50 | $-0.65 | $-0.15 |
| Jun 2025 | $-0.43 | $-0.50 | $-0.07 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | -$8.7M | -$10.1M | -$14.3M | -$16.3M | -$21.7M | — |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.4% | -31.8% | -34.4% | -34.4% | -34.4% | -32.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | — | 24.30 | 24.30 | 24.30 | 24.30 | 24.30 |
Key Ratios
ROA (TTM)
-31.2%
P/B
13.3
EPS (TTM)
$-1.52
52W High
$162.00
52W Low
$49.00
$49.00
52-Week Range
$162.00
Financial Health
Free Cash Flow
-$4.6M
Net Debt
-$156.5M
Cash
$157.0M
Total Debt
$510K
As of Sep 30, 2025
How does BLTE compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
BLTE valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
—
▼
0%
below
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
13.3
▲
154%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
BLTE profitability vs Pharmaceuticals peers
ROE
-32.5%
▼
24%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-1.5%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(88.9%)
vs Peers
vs Industry
Top tier
ROA
-31.2%
▼
230%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
BLTE financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
24.3
▲
598%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
-1.4
▼
342%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
BLTE fundamentals radar
BLTE
Peer median
Industry
BLTE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BLTE vs peers: key metrics
Top Holders
Top 5: 13.09%Darwin Global Management, L…
7.70%
$460.4M
RTW Investments LP
1.82%
$108.8M
Millennium Management Llc
1.42%
$85.0M
RA Capital Management, L.P.
1.10%
$65.8M
Perceptive Advisors Llc
1.05%
$63.0M
As of Dec 31, 2025